Article ID Journal Published Year Pages File Type
3360435 International Journal of Antimicrobial Agents 2008 19 Pages PDF
Abstract

In the current context of increasing antimicrobial resistance, it is important to use antibiotics rationally and to re-assess regularly the clinical usefulness of commonly used agents. This review focuses on the efficacy of the β-lactam ampicillin co-administered with the β-lactamase inhibitor sulbactam, either parenterally (ampicillin/sulbactam) or orally (sultamicillin), for the treatment of bacterial infections. Clinical findings from the past decade confirm the results of numerous older studies and together provide good evidence to support the continued use of ampicillin/sulbactam and sultamicillin in hospital- and community-acquired infections both in adults and children. This is also recognised in recent published national and international guidelines, many of which recommend ampicillin/sulbactam as first-line therapy for various respiratory and skin infections.

Related Topics
Life Sciences Immunology and Microbiology Applied Microbiology and Biotechnology
Authors
,